Oncology
Pharma Enters
into
License
Agreement for Small
Molecules Intellectual
Property for
the Treatment of Colon Cancer
San Francisco,
CA -- May 7, 2021 -- InvestorsHub NewsWire
-- Oncology
Pharma Inc. (OTC:
ONPH) ONPH has entered into a
licensing agreement with Regen BioPharma, Inc. for a technology
utilizing small molecules to activate immune checkpoints for the
treatment of colon cancer. The program entails
identifying small molecules that inhibit the NR2F6 nuclear
receptor. The NR2F6 nuclear receptor
has been identified as a potentially critical immune cell inhibitor
(an immune checkpoint) and cancer stem cell differentiator.
Regen BioPharma believes that by inhibiting
the NR2F6 nuclear receptor, one can unleash the cancer-killing
potential of a patient's own immune system. Regen is also engaged in the
identification of small molecules which activate the NR2F6 nuclear
receptor that can be utilized to develop small molecule therapies
for autoimmune disorders.
Small molecule
drugs have been the mainstay of the pharmaceutical industry for
nearly a century. Defined
as any organic compound with low molecular weight, small molecule
drugs have some distinct advantages as therapeutics, and
performing
development
is of
immense value to the big pharmaceutical companies.
Oncology
Pharma is delighted to add this IP to its portfolio of assets that
addresses therapeutics in what can lead to expanding both time and
the quality of life for cancer patients.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may
include onerous terms; unexpected costs and operating deficits, and
lower than expected sales and revenues; uncertain willingness and
ability of customers to adopt new technologies and other factors
that may affect further market acceptance; adverse economic
conditions; adverse results of any legal proceedings; the
volatility of our operating results and financial condition;
inability to attract or retain qualified senior management
personnel, including sales and marketing personnel; our ability to
establish and maintain the proprietary nature of our technology
through the patent process, as well as our ability to possibly
license from others patents and patent applications necessary to
develop products; the Company's ability to implement its long range
business plan for various applications of its technology; the
Company's ability to enter into agreements with any necessary
marketing and/or distribution partners and with any strategic or
joint venture partners; the impact of competition; the obtaining
and maintenance of any necessary regulatory clearances applicable
to applications of the Company's technology; management of growth;
and, other risks and uncertainties. This is not a solicitation to
buy or sell securities and does not purport to be an analysis of
the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com